NCT06998056 Phase 2 Completed
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2025-12-04 Actual
Enrollment · participants 101 Actual
Source updated 2025-12-10 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2025-12-10 · 5 fields changed
Participant count type Recorded edit − Previous value Estimated
Enrollment · participant count Recorded edit − Previous value count: 100; type: ESTIMATED
+ Updated value count: 101; type: ACTUAL
Completion date type Recorded edit − Previous value Estimated
Primary completion date Recorded edit + Updated value 2025-12-04
Recruitment status Recorded edit − Previous value Recruiting
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial